Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Website: tyra.bio




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1.4% (LTM)

Entry Point: Share price is 197.9% higher than minimum and 50.0% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $3.8 mln (-0.529% of cap.)

Key Financials (Download financials)

Ticker: TYRA
Share price, USD:  (+3.7%)15.67
year average price 14.79  


year start price 14.18 2023-05-01

min close price 11.01 2023-10-26

max close price 20.00 2024-03-04

current price 15.67 2024-04-29
Common stocks: 41 883 904

Dividend Yield:  0.0%
Last revenue growth (y/y):  ---
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 656
Net Debt ($m): -301
EV (Enterprise Value): 355
Price to Book: 3.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-06-07Zacks Investment Research

Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet

2023-06-01Seeking Alpha

Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules

2023-05-25PRNewsWire

Tyra Biosciences to Participate in Upcoming Investor Conferences

2023-05-23Zacks Investment Research

What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TYRA TYRA TYRA TYRA TYRA TYRA
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-19 2023-11-07 2023-08-10 2023-05-04 2023-03-22 2022-11-03
acceptedDate 2024-03-19 16:09:27 2023-11-07 16:16:24 2023-08-10 16:27:15 2023-05-04 16:16:08 2023-03-22 16:16:02 2022-11-03 16:34:30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0
costOfRevenue 102 000 82 000 86 000 0 0 0
grossProfit -102 000 -82 000 -86 000 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 21M 19M 12M 10M 10M 11M
generalAndAdministrativeExpenses 5M 5M 4M 4M 5M 3M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 4M 4M 5M 3M
otherExpenses -11 000 -5000.000 -21 000 -1000.000 -33 000 0
operatingExpenses 26M 24M 16M 14M 15M 14M
costAndExpenses 26M 24M 16M 14M 15M 14M
interestIncome 3M 3M 3M 2M 2M 1M
interestExpense 0 0 0 -2M -1M 1M
depreciationAndAmortization 102 000 82 000 86 000 83 000 82 000 82 000
ebitda -26M -24M -16M -14M -15M -14M
ebitdaratio 0 0 0 0 0 0
operatingIncome -26M -24M -16M -14M -15M -14M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet 3M -5000.000 -21 000 2M 2M 1M
incomeBeforeTax -23M -21M -13M -12M -13M -13M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense 0 -3M -3M -2M -32M -1M
netIncome -23M -21M -13M -9M 19M -11M
netIncomeRatio 0 0 0 0 0 0
eps -0.530 -0.490 -0.310 -0.220 0.460 -0.270
epsdiluted -0.530 -0.490 -0.310 -0.220 0.460 -0.270
weightedAverageShsOut 43M 43M 43M 42M 42M 42M
weightedAverageShsOutDil 43M 43M 43M 42M 42M 42M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TYRA TYRA TYRA TYRA TYRA TYRA
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-19 2023-11-07 2023-08-10 2023-05-04 2023-03-22 2022-11-03
acceptedDate 2024-03-19 16:09:27 2023-11-07 16:16:24 2023-08-10 16:27:15 2023-05-04 16:16:08 2023-03-22 16:16:02 2022-11-03 16:34:30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 58M 216M 232M 242M 251M 263M
shortTermInvestments 145M 0 0 0 0 0
cashAndShortTermInvestments 203M 216M 232M 242M 251M 263M
netReceivables 700 000 0 0 0 0 0
inventory 0 0 0 0 0 0
otherCurrentAssets 8M 9M 8M 5M 6M 4M
totalCurrentAssets 212M 225M 241M 242M 257M 267M
propertyPlantEquipmentNet 8M 7M 7M 3M 4M 4M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 1 000 000 1 000 000 1 000 000 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 5M 5M 866 000 5M 5M 5M
totalNonCurrentAssets 14M 14M 9M 8M 9M 9M
otherAssets 0 0 0 -351M 0 0
totalAssets 226M 238M 250M -101M 266M 276M
accountPayables 5M 2M 1M 1M 1M 3M
shortTermDebt 280 000 148 000 144 000 144 000 140 000 127 000
taxPayables 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 10M 8M 4M 834 000 4M 3M
totalCurrentLiabilities 15M 10M 5M 2M 6M 5M
longTermDebt 6M 6M 6M 2M 2M 3M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 45 999 77 000 108 000 139 000 169 000 -134 000
totalNonCurrentLiabilities 6M 6M 6M 3M 3M 3M
otherLiabilities 1.000 0 0 -3M 0 0
capitalLeaseObligations 6M 6M 6M 3M 3M 3M
totalLiabilities 22M 16M 11M 2M 8M 8M
preferredStock 0 0 0 0 0 0
commonStock 4000.000 4000.000 4000.000 4000.000 4000.000 4000.000
retainedEarnings -165M -142M -121M -108M -96M -83M
accumulatedOtherComprehensiveIncomeLoss 381 000 0 0 0 0 0
othertotalStockholdersEquity 369M 364M 359M -4000.000 -4000.000 351M
totalStockholdersEquity 204M 222M 239M -108M -96M 268M
totalEquity 204M 222M 239M -108M -96M 268M
totalLiabilitiesAndStockholdersEquity 226M 238M 250M -101M -87M 276M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 226M 238M 250M -101M -87M 276M
totalInvestments 146M 1 000 000 1 000 000 0 0 0
totalDebt 6M 6M 6M 3M 3M 3M
netDebt -52M -210M -226M -239M -249M -261M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TYRA TYRA TYRA TYRA TYRA TYRA
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-19 2023-11-07 2023-08-10 2023-05-04 2023-03-22 2022-11-03
acceptedDate 2024-03-19 16:09:27 2023-11-07 16:16:24 2023-08-10 16:27:15 2023-05-04 16:16:08 2023-03-22 16:16:02 2022-11-03 16:34:30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -23M -21M -13M -12M -13M -13M
depreciationAndAmortization 102 000 82 000 86 000 83 000 82 000 82 000
deferredIncomeTax -4M 0 0 0 6M 0
stockBasedCompensation 4M 4M 3M 2M 3M 1M
changeInWorkingCapital 6M -453 000 1M -483 000 -2M -805 000
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables 0 0 0 -2M 207 000 48 000
otherWorkingCapital 6M -453 000 1M 2M -2M -853 000
otherNonCashItems 3M 1000.000 3000.000 0 -6M 1000.000
netCashProvidedByOperatingActivities -14M -17M -10M -10M -12M -12M
investmentsInPropertyPlantAndEquipment -603 000 -83 000 -43 000 -41 000 -21 000 -48 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments -144M 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites -143 835 0 0 0 0 0
netCashUsedForInvestingActivites -144M -83 000 -43 000 -41 000 -21 000 -48 000
debtRepayment 0 0 0 0 0 0
commonStockIssued 324 000 467 000 370 000 376 000 -629 000 364 000
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 324.000 467.000 0 0 632 000 0
netCashUsedProvidedByFinancingActivities 324 000 467 000 370 000 376 000 3000.000 364 000
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash -158M -17M -9M -10M -12M -12M
cashAtEndOfPeriod 58M 217M 233M 243M 252M 264M
cashAtBeginningOfPeriod 216M 233M 243M 252M 264M 276M
operatingCashFlow -14M -17M -10M -10M -12M -12M
capitalExpenditure -603 000 -83 000 -43 000 -41 000 -21 000 -48 000
freeCashFlow -14M -17M -10M -10M -12M -12M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-19 20:05 ET
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
2024-02-27 21:05 ET
Tyra Biosciences to Present at Upcoming Investor Conferences
2024-02-07 21:05 ET
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
2024-02-02 13:00 ET
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
2024-02-01 22:30 ET
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
2023-12-22 14:00 ET
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
2023-11-08 21:05 ET
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
2023-11-07 21:05 ET
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
2023-09-21 12:00 ET
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
2023-09-12 20:05 ET
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
2023-08-10 20:05 ET
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
2023-08-01 12:00 ET
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia
2023-05-25 12:00 ET
Tyra Biosciences to Participate in Upcoming Investor Conferences
2023-05-04 20:05 ET
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
2023-03-29 20:05 ET
Tyra Biosciences to Participate in Upcoming Investor Conferences
2023-03-22 20:05 ET
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
2023-03-01 12:00 ET
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
2023-02-22 21:05 ET
Tyra Biosciences to Present at Upcoming Investor Conferences
2022-11-29 12:00 ET
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
2022-11-10 21:20 ET
Tyra Biosciences to Present at Upcoming Investor Conferences
2022-11-03 20:05 ET
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
2022-11-02 20:05 ET
Tyra Biosciences Announces Planned Chief Financial Officer Transition
2022-10-13 12:00 ET
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2022-09-08 20:05 ET
Tyra Biosciences to Participate at September 2022 Investor Conferences
2022-09-05 12:15 ET
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
2022-08-04 20:05 ET
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
2022-05-05 20:05 ET
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
2022-03-03 21:05 ET
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
2022-02-22 21:05 ET
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference
2021-11-10 21:05 ET
Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference
2021-11-03 20:05 ET
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights
2021-09-17 20:05 ET
Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
2021-09-15 01:00 ET
Tyra Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-03-19 16:09 ET
Tyra Biosciences, Inc. reported for 2023 q4
SEC form 8
2024-03-19 16:05 ET
Tyra Biosciences, Inc. reported for 2023 q4
SEC form 8
2024-03-19 16:05 ET
Tyra Biosciences, Inc. published news for 2023 q4
SEC form 10
2024-03-19 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q4
SEC form 10
2023-11-07 16:16 ET
Tyra Biosciences, Inc. reported for 2023 q3
SEC form 8
2023-11-07 16:07 ET
Tyra Biosciences, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q3
SEC form 10
2023-08-10 16:27 ET
Tyra Biosciences, Inc. published news for 2023 q2
SEC form 6
2023-08-10 16:21 ET
Tyra Biosciences, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Tyra Biosciences, Inc. published news for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q2
SEC form 8
2023-05-04 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q1
SEC form 10
2023-03-22 16:16 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 6
2023-03-22 16:05 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 10
2023-03-22 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 6
2023-03-01 07:30 ET
Tyra Biosciences, Inc. published news for 2022 q4
SEC form 6
2022-11-29 08:06 ET
Tyra Biosciences, Inc. published news for 2022 q3
SEC form 10
2022-11-03 16:34 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-11-03 16:16 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-10-03 16:43 ET
Tyra Biosciences, Inc. published news for 2022 q3
SEC form 10
2022-08-04 16:35 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-08-04 16:23 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-06-14 16:01 ET
Tyra Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-05-05 16:32 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 6
2022-05-05 16:17 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
Tyra Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-03-03 16:31 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 6
2022-03-03 16:16 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 10
2022-03-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 8
2022-03-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 10
2021-11-03 16:31 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-11-03 16:16 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-09-17 16:01 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:21 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:21 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:20 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:19 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:19 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:18 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:17 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:17 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:17 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:15 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:15 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:14 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:13 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:12 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:11 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 18:45 ET
Tyra Biosciences, Inc. published news for 2021 q2